NETCORE-CLOUD
30.3.2022 11:32:11 CEST | Business Wire | Press release
Netcore Cloud , a profitable SaaS company and global leader in customer communication, engagement, and retention, bets big on Personalization with its investment of close to $100 mn to acquire a majority stake in US-based, search-personalization company Unbxd Inc. It will also be infusing additional funding into Unbxd to propel the company's growth in developed markets.
Founded by Pavan Sondur and Prashant Kumar in 2012, Unbxd is a 120-member team and has built a best-in-class AI-powered Product Discovery suite. Its intelligent search solutions significantly improve retention and conversions for leading eCommerce retailers/B2C brands in the USA, UK, and Australia, including marquee brands like Mattress Firm, Express, Ashley Homestore, Home Shopping Network, Advance Auto Parts, The Children's Place, Mitre10, Kookai, and many others.
Netcore Cloud, has ranked a strong performer globally in email marketing by Forresterwave, commands 75% of India's & 50% of Asia's email traffic on its platform. With Unbxd's expertise in product discovery, the investment positions Netcore Cloud's as a leading Digital Experience Platform (DXP) globally. Leveraging Unbxd's AI-powered search expertise equips Netcore Cloud to deliver a real-time recommendation to its online eCommerce/app-first brand and retailer.
"The coming MarTech era will be defined by budget shifts from Adtech to MarTech as brands will focus more on unit economics and valuing existing customers. This will lead D2C/eCommerce brands to accelerate their spending towards delivering personalized customer experiences. Unbxd's AI/ML tech stack will empower our customers to track their shopper’s interactions with Search and implement site-wide Personalization, merchandising, along with shopper-focused recommendations. This will enable brands to optimize their entire customer journey, providing the best in class customer experience," said Kalpit Jain, Group CEO, Netcore Cloud.
"Netcore Cloud platform is growing rapidly at 40% YoY (with international markets growing 100% YoY ). We are positioned as the digital proxy in emerging markets. Added to that, this investment will enable us to get a strong foothold in the US and other developed markets as well. Furthermore, the combination of Unbxd and Netcore Cloud's capabilities will bolster our full-stack product offerings,” said Nishant Jain, Chief Strategy Officer and Head of M&A, Netcore Cloud.
He further added, “The SaaS market is very fragmented, and the era of SaaS consolidation is upon us. We intend to fast-track our growth exponentially with the Buy-Partner strategy. This is our fourth acquisition in quick succession, and we already have our eyes set on the next one.”
Pavan Sondur and Prashant, Co-founders at Unbxd, said, "Since our launch, we at Unbxd have been on a mission to solve the problem of discovery for digital commerce leveraging the power of AI. With our unique combination of personalization solutions and Netcore's robust full-stack marketing automation tech platform, it's a perfect partnership that can capture cross-selling opportunities and scale the business globally.
Netcore Cloud has confirmed that there will be no change in the company's management, as the founders and key management will continue to build and grow the company post this deal. Unbxd will operate as an independent entity.
About Netcore Cloud:
Netcore Cloud is a bootstrapped SaaS company that helps B2C brands and marketers create AI-powered new-age customer experiences at every touchpoint of a customer's journey. Netcore Cloud's full-stack marketing platform enables highly personalized digital experiences that are easily scalable and provide actionable analytics, real-time reporting, and quick to implement solutions across channels. Brands using Netcore Cloud can have a unified view of their customers and optimize their user experience.
Headquartered in Mumbai, India, with 11 offices across the USA, Singapore, Malaysia, Nigeria, Indonesia, UAE, UK, and Germany, Netcore Cloud serves 5000+ customers across the globe. It delivers 17+ billion emails and tracks 100+ billion marketing events every month. Netcore Cloud is a trusted partner across industries with some of the most respected brands like MaxLife Insurance, ICICI Bank, Standard Chartered, Flipkart, Myntra, Miss Amara, Airtel, Disney Hotstar, Canon, Puma, Tobi, EaseMyTrip, PizzaHut and McDonald's. For more information, visit https://netcorecloud.com/
About Unbxd:
Unbxd is an eCommerce product discovery platform to help online retailers provide a seamless shopping experience to customers. The company deploys self-learning AI/ML models and advanced algorithms to deliver personal recommendation and merchandising controls. Presently, the company empowers 3.5% of all US e-commerce on-site search queries spread over 150+ customers. The company has a wide presence in 40+ countries and provides intelligent site search to more than 1,200 eCommerce sites.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005966/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom